Gene therapy and stem cell therapy for cardiovascular diseases today: A model for translational research

被引：5

作者：

Fuster V. ^{[1
]}

Sanz J. ^{[1
]}

机构：

[1] The Zena and Michael A Wiener Cardiovascular Institute, The Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY

来源：

Nature Clinical Practice Cardiovascular Medicine | 2007年 / 4卷 / Suppl 1期

关键词：

D O I：

10.1038/ncpcardio0737

中图分类号：

学科分类号：

摘要：

Clinical trials looking at ways to promote myocardial regeneration have reported that the administered therapies have either neutral effects or modest benefits of questionable impact. These somewhat disappointing results should emphasize the need for translational research, with bidirectional feedback between the basic research laboratory and the clinical arena. Such a translational pathway is illustrated by the quest to find an effective therapy for restenosis, which culminated in the development of sirolimus. At this point a move away from the bedside and a return to the bench seems necessary to better understand the mechanisms of action of progenitor cells and stimulating factors. Without such basic knowledge research might be prematurely discouraged and the opportunity to fully understand the true potential of cardiovascular regenerative therapy might be missed.

引用

页码：S1 / S8

页数：7

共 51 条

[1]

Lefkowitz R.J., Willerson J.T., Prospects for cardiovascular research, JAMA, 285, pp. 581-587, (2001)

[2]

Smith Jr. S.C., Et al., ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - Executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty), Circulation, 103, pp. 3019-3041, (2001)

[3]

Marx S.O., Marks A.R., Bench to bedside: The development of rapamycin and its application to stent restenosis, Circulation, 104, pp. 852-855, (2001)

[4]

Poon M., Et al., Overcoming restenosis with sirolimus: From alphabet soup to clinical reality, Lancet, 359, pp. 619-622, (2002)

[5]

Gallo R., Et al., Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle, Circulation, 99, pp. 2164-2170, (1999)

[6]

Worthley S.G., Et al., Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model, Circulation, 101, pp. 2956-2961, (2000)

[7]

Babapulle M.N., Et al., A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents, Lancet, 364, pp. 583-591, (2004)

[8]

Abizaid A., Et al., Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the Arterial Revascularization Therapy Study (ARTS) Trial, Circulation, 104, pp. 533-538, (2001)

[9]

Moses J.W., Et al., Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery, N Engl J Med, 349, pp. 1315-1323, (2003)

[10]

Stone G.W., Et al., A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N Engl J Med, 350, pp. 221-231, (2004)

← 1 2 3 4 5 6 →